PandaOmics

✈ The latest from PandaOmics! Introducing PandaOmics Box. Transform the #research landscape, empowering researchers to excel in target identification, biomarker discovery and indication prioritization. Hear from Insilico Medicine's CEO, Alex Zhavoronkov to learn more about this new #drugdiscovery toolkit. Visit our website today: https://lnkd.in/dsviKa7e

⚡ PandaOmics: Integration within the Pharma.AI Ecosystem PandaOmics plays a crucial role in the Pharma.AI ecosystem by Insilico Medicine, working in tandem with other tools, such as Chemistry42 and inClinico. Chemistry42 is a #generativechemistry platform that leverages artificial intelligence to facilitate the automated generation of small molecule compounds for drug discovery. By integration with Chemistry42, PandaOmics utilizes the predicted protein structures generated by #AlphaFold to guide the compound generation process, enabling the rapid identification of potential hit molecules for novel targets. inClinico, and on the other hand, is a powerful platform for in silico prediction of clinical trial outcomes, providing a virtual testing environment for potential drug candidates. PandaOmics complements inClinico by providing essential insights into potential therapeutic targets and biomarkers. By leveraging the comprehensive data processing capabilities of PandaOmics, researchers can identify and prioritize targets that show promise for further evaluation in clinical trials using inClinico. This integration enables a seamless transition from target identification to compound generation and virtual testing, streamlining the drug discovery and development process. Overall, PandaOmics, Chemistry42, and inClinico collectively form the Pharma.AI ecosystem, offering an end-to-end solution for accelerating and optimizing key steps in drug discovery. From target identification and hit molecule generation using PandaOmics and Chemistry42, to virtual testing and simulation using inClinico, these tools work synergistically to enhance the efficiency and effectiveness of drug discovery efforts, ultimately leading to the development of novel therapeutics with improved success rates and reduced costs. For the full Application Note from the Journal of Chemical Information and Modeling, please visit: https://lnkd.in/dC2XZsHH

📚 Unlock Your Research Potential with Science42: DORA Are you an academic student looking to accelerate your research? Meet DORA—the AI-powered tool designed to simplify and enhance your discovery process. 🔍 Why Choose DORA? Gain insights across biology, chemistry, and pharmacology Access AI-driven tools for hypothesis generation and validation Collaborate effortlessly with peers 🎉 Special Offer: Academic discounts available—because innovation should be accessible to all. 👉 Learn more and start today. Your next breakthrough is just a click away! 🚀 https://pharma.ai/dora #AIInAcademia #ResearchTools #LifeSciences #DORA #Science42

Quote of the week 💬 Did you know that over 50% of drug discovery companies 🧬 are now integrating AI into their processes? In biotech, generative AI is revolutionizing molecule design, enabling researchers to create entirely new compounds with properties tailored to treat specific diseases—compounds that don’t exist in nature. This has the potential to cut drug development timelines by 40% ⏱️ and significantly reduce costs 💰. But the impact doesn’t stop at healthcare. AI is reshaping industries like manufacturing ⚙️, where predictive algorithms are improving efficiency by up to 30%, and renewable energy 🌱, optimizing systems to increase output by 20%. The possibilities are endless as AI transforms the way we innovate and solve global challenges. Which industry do you think will see the biggest AI-driven revolution next? 🤔 Source: https://bit.ly/3C2mQD7 #ArtificialIntelligence #AIStatistics #GenerativeAI #BiotechInnovation #FutureOfWork #TechForGood #AIForChange Alex Zhavoronkov Insilico Medicine

Great article from Pascal BOUQUET. Check it out for updates on the AI industry in a concise summary with links! Insilico Medicine PandaOmics Chemistry42 Generative Biologics

💡 “As a researcher often involved in #drugdiscovery efforts, I get the feeling that AI is truly a powerful helping hand in the biopharmaceutical industry,” says Jingjing Peng, PhD, the first author of the paper and a medicinal chemist at Insilico Medicine, “In our work, we utilized AI to systematically identify and optimize HPK1 inhibitors with enhanced potency and selectivity. The workflow was streamlined, and we were excited to see the constant improvement at each milestone.” 📜 In the first paper published in September 2024, the team employed #PandaOmics, the AI-powered discovery engine affiliated to Pharma.AI, which integrates over 20 AI #bioinformatic models and billions of data points, for #HPK1 target evaluation. Supported by the knowledge graph based on AI analysis, as well as previous studies, HPK1 is hypothesized to mitigate select immune responses, laying the foundation for further molecule design and synthesis. With a novel candidate compound identified with potent in vitro activity, markedly improved PK properties, strong in vivo anti-tumor activity and promising toxicity profiles, Insilico scientists achieved a starting point for further optimization of kinase selectivity and more properties. Read the full release here 👉 https://lnkd.in/eYdiBUqp

⚡ PandaOmics is Data Analysis #Omics Data Analysis Use our normalized and annotated Omics data collections. Focus on #dataanalysis and interpretation, not on pre-processing and hosting. Run target identification, indication, and compound prioritization; analyze differential expression to prioritize significantly under or over-expressed genes in sample groups. Dive deeper into PandaOmics today 👉 https://lnkd.in/eSq5CrqA

Our dear customers, partners, and collaborators using the Pharma.AI platform. Our platform teams in charge of PandaOmics, Chemistry42, inClinico, Precious3GPT, DORA, Science42 Sustainability Consortium and the foundational models salute you 🫡 and wish you Happy Holidays and Happy New Year! 🥳

☃️ Happy Holidays from the #PandaOmics team! Wishing you a happy and healthy New Year. 🎄

❄️ Winter Savings for Academia – Unlock the Power of PandaOmics! ❄️ This winter, we’re making it easier than ever for academic researchers to harness the power of AI for their drug discovery projects. For a limited time, enjoy exclusive academic discounts on PandaOmics! 🔍 Discover new therapeutic targets with AI-powered precision 📚 Streamline your research with an intuitive platform built for innovation 💡 Accelerate breakthroughs in your lab or institution Take advantage of these savings to make the most of your research budget this season! 👉 Explore PandaOmics Winter Discounts: https://lnkd.in/eSq5CrqA #AcademicResearch #AIinDrugDiscovery #PharmaAI #WinterSavings